Novel combination therapy effective for NRAS mutant and therapy resistant melanoma

(The Wistar Institute) Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO Molecular Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news